CLDX
Price
$18.30
Change
+$0.50 (+2.81%)
Updated
Apr 17 closing price
Capitalization
1.21B
12 days until earnings call
INVA
Price
$18.27
Change
+$0.18 (+1.00%)
Updated
Apr 17 closing price
Capitalization
1.15B
4 days until earnings call
Ad is loading...

CLDX vs INVA

Header iconCLDX vs INVA Comparison
Open Charts CLDX vs INVABanner chart's image
Celldex Therapeutics
Price$18.30
Change+$0.50 (+2.81%)
Volume$457.87K
Capitalization1.21B
Innoviva
Price$18.27
Change+$0.18 (+1.00%)
Volume$738.25K
Capitalization1.15B
CLDX vs INVA Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. INVA commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and INVA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (CLDX: $18.30 vs. INVA: $18.27)
Brand notoriety: CLDX and INVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 57% vs. INVA: 78%
Market capitalization -- CLDX: $1.21B vs. INVA: $1.15B
CLDX [@Biotechnology] is valued at $1.21B. INVA’s [@Biotechnology] market capitalization is $1.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileINVA’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • INVA’s FA Score: 1 green, 4 red.
According to our system of comparison, INVA is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 5 TA indicator(s) are bullish while INVA’s TA Score has 4 bullish TA indicator(s).

  • CLDX’s TA Score: 5 bullish, 3 bearish.
  • INVA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than INVA.

Price Growth

CLDX (@Biotechnology) experienced а +14.81% price change this week, while INVA (@Biotechnology) price change was +6.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

CLDX is expected to report earnings on Aug 07, 2025.

INVA is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.22B) has a higher market cap than INVA($1.15B). INVA YTD gains are higher at: 5.303 vs. CLDX (-27.582). INVA has higher annual earnings (EBITDA): 85.5M vs. CLDX (-191.9M). CLDX has more cash in the bank: 725M vs. INVA (412M). CLDX has less debt than INVA: CLDX (3.81M) vs INVA (451M). INVA has higher revenues than CLDX: INVA (359M) vs CLDX (7.02M).
CLDXINVACLDX / INVA
Capitalization1.22B1.15B106%
EBITDA-191.9M85.5M-224%
Gain YTD-27.5825.303-520%
P/E RatioN/A50.75-
Revenue7.02M359M2%
Total Cash725M412M176%
Total Debt3.81M451M1%
FUNDAMENTALS RATINGS
CLDX vs INVA: Fundamental Ratings
CLDX
INVA
OUTLOOK RATING
1..100
519
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
6443
SMR RATING
1..100
9385
PRICE GROWTH RATING
1..100
8548
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/a21

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (59) in the Biotechnology industry is in the same range as INVA (76) in the Pharmaceuticals Other industry. This means that CLDX’s stock grew similarly to INVA’s over the last 12 months.

INVA's Profit vs Risk Rating (43) in the Pharmaceuticals Other industry is in the same range as CLDX (64) in the Biotechnology industry. This means that INVA’s stock grew similarly to CLDX’s over the last 12 months.

INVA's SMR Rating (85) in the Pharmaceuticals Other industry is in the same range as CLDX (93) in the Biotechnology industry. This means that INVA’s stock grew similarly to CLDX’s over the last 12 months.

INVA's Price Growth Rating (48) in the Pharmaceuticals Other industry is somewhat better than the same rating for CLDX (85) in the Biotechnology industry. This means that INVA’s stock grew somewhat faster than CLDX’s over the last 12 months.

INVA's P/E Growth Rating (2) in the Pharmaceuticals Other industry is significantly better than the same rating for CLDX (100) in the Biotechnology industry. This means that INVA’s stock grew significantly faster than CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXINVA
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
57%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
64%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
59%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
67%
Declines
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 11 days ago
63%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
67%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SEKCX15.640.22
+1.43%
DWS Emerging Markets Equity C
MRSJX23.280.17
+0.74%
MFS Research International R4
HSLSX34.370.21
+0.61%
Hartford Small Cap Growth R4
OGICX34.020.17
+0.50%
Invesco Global Opportunities C
UGTAX25.970.03
+0.12%
Victory Growth and Tax Strategy A

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with DNLI. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+2.81%
DNLI - CLDX
51%
Loosely correlated
+1.51%
KYMR - CLDX
49%
Loosely correlated
+3.80%
BEAM - CLDX
48%
Loosely correlated
+2.29%
NTLA - CLDX
47%
Loosely correlated
+5.39%
ATXS - CLDX
46%
Loosely correlated
+1.51%
More

INVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, INVA has been loosely correlated with SGMO. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if INVA jumps, then SGMO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INVA
1D Price
Change %
INVA100%
+1.00%
SGMO - INVA
40%
Loosely correlated
+2.96%
REGN - INVA
35%
Loosely correlated
+2.53%
DTIL - INVA
34%
Loosely correlated
+0.20%
INSM - INVA
33%
Loosely correlated
+3.49%
CLDX - INVA
33%
Loosely correlated
+2.81%
More